García-Rodríguez S, Arias-Santiago S, Perandrés-López R, Orgaz-Molina J, Castellote L, Buendía-Eisman A, Ruiz J C, Naranjo R, Navarro P, Sancho J, Zubiaur M
Departamento de Biología Celular e Inmunología, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain.
Actas Dermosifiliogr. 2013 Jul-Aug;104(6):497-503. doi: 10.1016/j.ad.2012.11.019. Epub 2013 Mar 21.
Psoriasis is a chronic inflammatory disease that has been linked to increased cardiovascular risk. The glycoprotein clusterin (apolipoprotein J) is a component of high-density lipoproteins and has a protective role in atherosclerosis. The aim of the present study was to evaluate the plasma levels of clusterin and the proinflammatory cytokine macrophage migration inhibitory factor (MIF) in patients with severe psoriasis, comparing groups of patients with different risks of cardiovascular disease.
Twenty-one patients with severe psoriasis (psoriasis area severity index and body surface area>10) and 11 healthy controls with no dermatologic disease were studied. Cardiovascular risk factors were assessed according to the Adult Treatment Panel (ATP) III criteria. Subclinical carotid atheromatosis was assessed by Doppler ultrasonography of the carotid arteries. Plasma clusterin and MIF levels were measured by enzyme-linked immunosorbent assay.
ATP-III criteria for metabolic syndrome were met by 47% of the patients, and 33% had carotid atheromatous plaque. Mean (SD) clusterin plasma levels were significantly lower in patients with psoriasis compared with controls (81.39 [27.30] μg/mL for the 21 patients vs 117 [21.6] μg/mL for the 11 controls; P=.0017). MIF plasma levels (ng/ml) were significantly higher in patients with atheromatous plaque compared with controls (53.22 [29.02] for the 6 patients with plaque vs 34.21 [9.65] for the 11 controls; P=.0394).
The decreased plasma levels of clusterin in psoriatic patients suggested an association with the disease and might be an indicator of systemic inflammatory activity. Increased levels of MIF appear to be associated with cardiovascular risk factors and carotid atheromatous plaque.
银屑病是一种慢性炎症性疾病，与心血管疾病风险增加有关。糖蛋白簇集素（载脂蛋白J）是高密度脂蛋白的一个组成部分，在动脉粥样硬化中具有保护作用。本研究的目的是评估重度银屑病患者血浆中簇集素和促炎细胞因子巨噬细胞移动抑制因子（MIF）的水平，并比较具有不同心血管疾病风险的患者组。
研究了21例重度银屑病患者（银屑病面积严重指数和体表面积>10）和11例无皮肤病的健康对照者。根据成人治疗小组（ATP）III标准评估心血管危险因素。通过颈动脉多普勒超声评估亚临床颈动脉粥样硬化。采用酶联免疫吸附测定法测量血浆簇集素和MIF水平。
47%的患者符合ATP-III代谢综合征标准，33%有颈动脉粥样斑块。银屑病患者的平均（标准差）血浆簇集素水平显著低于对照组（21例患者为81.39[27.30]μg/mL，11例对照组为117[21.6]μg/mL；P=0.0017）。有粥样斑块的患者血浆MIF水平（ng/ml）显著高于对照组（6例有斑块的患者为53.22[29.02]，11例对照组为34.21[9.65]；P=0.0394）。
银屑病患者血浆簇集素水平降低表明与该疾病有关，可能是全身炎症活动的一个指标。MIF水平升高似乎与心血管危险因素和颈动脉粥样斑块有关。
